Volume | 45,518 |
|
|||||
News | (1) | ||||||
Day High | 2.32 | Low High |
|||||
Day Low | 2.18 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
BeyondSpring Inc | BYSI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.18 | 2.18 | 2.32 | 2.25 | 2.1601 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
258 | 45,518 | US$ 2.26 | US$ 102,898 | - | 0.6534 - 4.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:05 | 2 | US$ 2.2504 | USD |
BeyondSpring Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
89.13M | 38.92M | - | 1.35M | -33.28M | -0.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BeyondSpring News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BYSI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.36 | 2.38 | 1.7343 | 2.12 | 24,038 | -0.11 | -4.66% |
1 Month | 2.7067 | 2.978 | 1.7343 | 2.19 | 71,046 | -0.4567 | -16.87% |
3 Months | 1.14 | 4.00 | 1.05 | 2.81 | 236,351 | 1.11 | 97.37% |
6 Months | 0.9367 | 4.00 | 0.7777 | 2.50 | 132,305 | 1.31 | 140.20% |
1 Year | 0.9609 | 4.00 | 0.6534 | 2.01 | 98,263 | 1.29 | 134.16% |
3 Years | 10.90 | 33.00 | 0.542 | 13.34 | 669,977 | -8.65 | -79.36% |
5 Years | 14.72 | 33.00 | 0.542 | 13.30 | 457,655 | -12.47 | -84.71% |
BeyondSpring Description
BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China. |